CPI Antitrust Chronicle (Nov. 2014)
12 Pages Posted: 25 Nov 2014
Date Written: November 24, 2014
The pharmaceutical industry is unique in its complexity. Markets are nuanced. Multiple regulatory regimes apply. Generic entry is an event with dramatic consequences. These characteristics have encouraged brand-name drug firms to engage in an array of conduct that exploits this complexity to delay generic entry.
This essay discusses these issues, focusing on two activities: (1) “product hopping” from one version of a drug to another and (2) settlements by which brands pay generics to delay entry.
Keywords: pharmaceuticals, drugs, antitrust, complexity, settlements, product hopping, generics
JEL Classification: I18, K21, L40, L41, L43, L65, O34, O38
Suggested Citation: Suggested Citation
Carrier, Michael A., Pharmaceutical Antitrust Complexity (November 24, 2014). CPI Antitrust Chronicle (Nov. 2014). Available at SSRN: https://ssrn.com/abstract=2530169
By John Newman